Community-Acquired Pneumonia

The review evaluated randomized trial evidence for amoxicillin and amoxicillin-clavulanate in adults and children with CAP. Community-acquired pneumonia is a major contributor to morbidity and mortality, especially among young children. CAP is a leading cause of childhood hospitalisation in high-income countries and a leading cause of death among children in low- and middle-income countries. Empirical antibiotic guidance for CAP varies internationally and is influenced by severity and local epidemiology.